Stock Details
4519.T is Chugai Pharmaceutical Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 4,202.68¥. Average daily volumn in 3 months 2.69M. Market cap 6.80T



Stock symbol : 4519.T. Exchange : Tokyo. Currency : JPY
Lastest price : 4,135.00¥. Total volume : 1.90M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Chugai Pharmaceutical Co., Ltd. (4519.T)
Last Price
4,135.00¥
Change
6.00
Volume
1.90M

Previous Close4,129.00
Open4,142.00
Day Range4,096.00-4,167.00
Bid4,130.00 x N/A
Ask4,136.00 x N/A
Volume1.9M
Average Volume2.69M
Market Cap6.8T
Beta0.62
52 Week Range3,898.00-6,435.00
Trailing P/E32.30
Foward P/E3,975.96
Dividend (Yield %)1.44%
Ex-Dividend Date2021-12-29



Financial Details


According to Chugai Pharmaceutical Co., Ltd.'s financial reports the company's revenue in 2020 were 786.95B an increase( +14.58%) over the years 2019 revenue that were of 686.18B. In 2020 the company's total earnings were 214.73B while total earnings in 2019 were 157.56B( +36.31%).


Loading ...



Organization

The Chugai Pharmaceutical Co., Ltd. is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO.

Chugai Pharmaceutical Co., Ltd._logo

Market Cap:
6.80T
Revenue:
786.95B
Total Assets:
1.24T
Total Cash:
212.33B


News about "Chugai Pharmaceutical Co., Ltd."

Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and ...

Source from : NIKKEI - 6 days ago


Esoteric Testing Market Industry Development, Global Growth Demand, Challenges, Forecast and Strategies To 2030 | Chugai Pharmaceutical Co., Ltd._image

Esoteric Testing Market Industry Development, Global Growth Demand, Challenges, Forecast and Strategies To 2030 | Chugai Pharmaceutical Co., Ltd.

Global Esoteric Testing Market Overview Emerging technologies such as biomarker analysis digital PCR NGS pyrosequencing or Sanger sequencing digital microfluidic platforms and advanced molecular ...

Source from : openpr.com - 7 days ago


Verastem Oncology Appoints Louis J. Denis, M.D., as Chief Medical Officer

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Louis J. Denis, M.D., as Chief Medical Officer. Dr.

Source from : Le Lézard - 14 hours ago


Viscosupplementation Competitor Analysis Report - Global Forecast to 2026

The Global Viscosupplementation Market size was estimated at USD 2,394. 51 Million in 2020 and expected to reach USD 2,529. 65 Million in 2021, at a Compound Annual Growth Rate (CAGR) 5. 98% to reach ...

Source from : Yahoo Finance - 7 hours ago


Viscosupplementation Market 2021 | Present Scenario and Growth Prospects 2030

Research firm Future Market Insights’ recent coverage on viscosupplementation market for the assessment period 2020-2030 concludes that a revenue share of US$ 4 Bn will be attained by 2030-end. [...] ...

Source from : List of Banks in Belarus - 17 hours ago


Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response ...

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a mini ora ...

Source from : Business Wire - 3 days ago


Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lu

Clinical Collaboration Will Assess Safety and Efficacy of More Complete Vertical Blockade Along RAS PathwayBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company ...

Source from : 아크로팬 - 2 days ago


Verastem Oncology Announces Updated Investigator-...

Median progression-free survival (mPFS) across all patients treated with VS-6766 in combination with defactinib in the study is 23.0 months. 11 of 24 (46%) patients ...

Source from : Benzinga.com - 3 days ago


Chugai's ACTEMRA®/RoACTEMRA® Receives Breakthrough Therapy Designation from US FDA for Giant Cell Arteritis

-- The Fifth Breakthrough Therapy Designation Granted for a Chugai Originated Drug -- Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that the US Food and Drug Administration (FDA) has ...

Source from : ADVFN - 1 month ago


Human Herpesvirus 6-Associated Hemophagocytic Syndrome in a Healthy Adult

On day 14 after admission, at the onset of pancytopenia, subcutaneous administration of recombinant human G-CSF (Lenograstim; Chugai Pharmaceutical Co. LTD., Tokyo, Japan) was started at 2 µg/kg.

Source from : Medscape - 1 month ago


Chugai Pharmaceutical Co. Ltd. ADR

1 Day CHGCY 1.73% DJIA 0.76% S&P 500 0.23% Health Care/Life Sciences -0.66% Tatsuro Kosaka Chairman & Chief Executive Officer Chugai Pharmaceutical Co., Ltd., Asahi Group Holdings Ltd. Osamu Okuda ...

Source from : Wall Street Journal - 9 days ago


Chugai Pharmaceutical Co Ltd CUP

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Source from : Morningstar%2c Inc. - 6 days ago


Chugai Pharmaceutical Co Ltd ADR CHGCY

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Source from : Morningstar%2c Inc. - 6 days ago


Chugai Pharmaceutical Co., Ltd. (4519.T)

Inflation jumps to annual 3% in Europe as fuel costs rise ...

Source from : Yahoo Finance - 8 days ago


Chugai Pharmaceutical Co., Ltd. (4519.T)

S&P 500 falls 0.6% to pull back from record high and end 5-session winning streak ...

Source from : Yahoo Finance - 14 days ago


Chugai Pharmaceutical Co Ltd

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay Aug 22 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>::CHUGAI PHARMACEUTICAL - TECENTRIQ RECEIVES APPROVAL FOR ADDITIONAL ...

Source from : Reuters - 1 year ago


Chugai Pharmaceutical Co. Ltd. ADR

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Source from : Barron's - 14 days ago


Chugai Pharmaceutical Co., Ltd. (CHGCY)

*Close price adjusted for splits.**Adjusted close price adjusted for both dividends and splits. Loading more data ...

Source from : Yahoo Finance - 9 days ago


Chugai Pharmaceutical Co Ltd (CHGCF)

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Source from : Nasdaq - 2 month ago


Chugai Pharmaceutical Co Ltd (CHGCF)

©2021, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR ...

Source from : Nasdaq - 1 year ago


Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Sh

Median progression-free survival (mPFS) across all patients treated with VS-6766 in combination with defactinib in the study is 23.0 months. 11 of 24 (46%) patients treated with the combination ...

Source from : 아크로팬 - 3 days ago


Histology of Symptomatic Gastroesophageal Reflux Disease

In the present investigation, biopsy specimens were taken from 5 cm above the SCJ near the site of an indwelling sensor used for pH monitoring to detect morbid gastric acid reflux. This biopsy ...

Source from : Medscape - 5 days ago


Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

that we or Chugai Pharmaceutical Co., Ltd. will fail to fully perform under the VS-6766 license agreement; that we may not have sufficient cash to fund our contemplated operations; that we may be ...

Source from : Yahoo Finance - 1 month ago


Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview

a broad immunopotentiator marketed as Picibanil in Japan and Taiwan by Chugai Pharmaceutical Co., Ltd. Protara has successfully demonstrated initial manufacturing comparability between TARA-002 ...

Source from : wallstreet online - 1 month ago


Japan turns to antibody cocktails as 'new weapon' in fight against pandemic

The antibody treatment — originally developed by American biotech firm Regeneron Pharmaceuticals Inc. and licensed in Japan by Tokyo-based drugmaker Chugai Pharmaceutical Co. — has drawn ...

Source from : The Japan Times - 29 days ago


F. Hoffmann-La Roche Ltd: Roche opens access to pathology imaging tools to improve patient care

Roche launches the Digital Pathology Open Environment, encouraging collaboration among software developers to improve patient outcomes and expand personalised healthcare through innovative image analy ...

Source from : Finanznachrichten - 7 days ago


Roche opens access to pathology imaging tools to improve patient care_image

Roche opens access to pathology imaging tools to improve patient care

Roche launches the Digital Pathology Open Environment, encouraging collaboration among software developers to improve patient outcomes and expand personalised healthcare through innovative image ...

Source from : Yahoo Canada Sports - 7 days ago


Uveitis Drug Pipeline Landscape Research Report 2021 - ResearchAndMarkets.com

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is ...

Source from : PharmiWeb - 9 days ago


Uveitis Drug Pipeline Landscape Research Report 2021 - ResearchAndMarkets.com

The "Uveitis (Ophthalmology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering. Uveitis - Drugs In Development, 2021, provides an overview of the Uveitis ...

Source from : The Register-Herald - 9 days ago


Pegfilgrastim Market Share 2021 Strategy Analysis, Top Manufacturers, Industry Size, Types, Application, Growth Factor and Forecast to 2026

Is there a problem with this press release? Contact the source provider Comtex at [email protected] You can also contact MarketWatch Customer Service via our Customer Center. The MarketWatch ...

Source from : MarketWatch - 1 month ago


IP Forecast: Trial Lawyer School TM Fight Lands At 10th Circ.

Law360 (September 16, 2021, 8:06 PM EDT) -- Famed litigator Gerry Spence will ask a federal appeals court next week to reverse a trademark injunction in a bitter fight with his former legal ...

Source from : Law360 - 4 days ago


Porokeratosis Treatment Market is Surging on the Back Rising Focus on Skincare: Fact.MR

The global porokeratosis treatment market is demonstrating a steady growth due to surge demand for laser treatment, kidney transplant, and improved reimbursement policies. The distribution of actinic ...

Source from : PharmiWeb - 13 days ago


Global Hemophilia Treatment Drugs Market Research Report (2021 to 2026) - by Product Type, Disease Indication and Region - ResearchAndMarkets.com

The "Hemophilia Treatment Drugs Market Research Report by Product Type, by Disease Indication, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" report has been added to ...

Source from : thedailytimes.com - 6 days ago


Japan's Nikkei ends at near 6-month high on bargain hunting for cheap stocks

JFE Holdings, which fell 1.94%, was the worst performer on the index, followed by Chugai Pharmaceutical , losing 1.86% and Nippon Express, which fell 1.48%.

Source from : Yahoo Finance - 14 days ago


Uveitis Drug Pipeline Landscape Research Report 2021 - ResearchAndMarkets.com

DUBLIN, September 13, 2021--(BUSINESS WIRE)--The "Uveitis (Ophthalmology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering. Uveitis - Drugs In Development, 2021 ...

Source from : Yahoo Finance - 9 days ago


Symbol Lookup

TRIWX TIAA-CREF Large-Cap Growth Index Fund;W NAS TISWX TIAA-CREF S&P 500 Index Fund;W NAS TRIRX TIAA-CREF Large-Cap Growth Index Fund;Retirement NAS TILIX TIAA-CREF Large-Cap Growth Index Fund ...

Source from : MarketWatch - 5 days ago